HNSPF (Hansoh Pharmaceutical Group Co) Shares Outstanding (EOP): 6,054 Mil (As of Dec. 2025)


HNSPF Hansoh Pharmaceutical Group Co Ltd HNSPF
90 GF Score
Price $3.83
GF Value $3.00
Valuation Modestly Overvalued
View Full Analysis

What is Hansoh Pharmaceutical Group Co Shares Outstanding (EOP)?

Hansoh Pharmaceutical Group Co HNSPF 90 Shares Outstanding (EOP) is 6,054 Mil as of Dec. 2025. GuruFocus rates HNSPF with a GF Score™ of 90/100 and a GF Value™ of $3.00 (Modestly Overvalued).

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Hansoh Pharmaceutical Group Co's shares outstanding for the quarter that ended in Dec. 2025 was 6,054 Mil.

Hansoh Pharmaceutical Group Co's quarterly shares outstanding increased from Jun. 2025 (5,946 Mil) to Dec. 2025 (6,054 Mil). It means Hansoh Pharmaceutical Group Co issued new shares from Jun. 2025 to Dec. 2025 .

Hansoh Pharmaceutical Group Co's annual shares outstanding increased from Dec. 2024 (5,934 Mil) to Dec. 2025 (6,054 Mil). It means Hansoh Pharmaceutical Group Co issued new shares from Dec. 2024 to Dec. 2025 .


Hansoh Pharmaceutical Group Co  (OTCPK:HNSPF) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Hansoh Pharmaceutical Group Co Shares Outstanding (EOP) Related Terms


Hansoh Pharmaceutical Group Co Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for Hansoh Pharmaceutical Group Co's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hansoh Pharmaceutical Group Co Shares Outstanding (EOP) Chart

Hansoh Pharmaceutical Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5,922.35 5,919.95 5,923.74 5,934.34 6,053.96

Hansoh Pharmaceutical Group Co Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5,923.74 5,934.34 5,934.34 5,945.96 6,053.96

HNSPF vs ZTS, UTHR: Shares Outstanding (EOP) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Hansoh Pharmaceutical Group Co's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hansoh Pharmaceutical Group Co Shares Outstanding (EOP) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hansoh Pharmaceutical Group Co's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Hansoh Pharmaceutical Group Co's Shares Outstanding (EOP) falls into.


HNSPF
90GF Score
Hansoh Pharmaceutical Group Co Ltd HNSPF
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hansoh Pharmaceutical Group Co Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 6,054 Mil mean?
Hansoh Pharmaceutical Group Co (HNSPF) has a Shares Outstanding (EOP) of 6,054 Mil as of Dec. 2025. The total shares a company has outstanding, at period-end. View historical data on Hansoh Pharmaceutical Group Co and its competitors.
Is Hansoh Pharmaceutical Group Co's Shares Outstanding (EOP) too high?
Hansoh Pharmaceutical Group Co's current Shares Outstanding (EOP) is 6,054 Mil. Overall, Hansoh Pharmaceutical Group Co has a GF Score™ of 90/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hansoh Pharmaceutical Group Co's Shares Outstanding (EOP) compare to ZTS and UTHR?
Hansoh Pharmaceutical Group Co's Shares Outstanding (EOP) of 6,054 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Drug Manufacturers company?
A good Shares Outstanding (EOP) depends on the Drug Manufacturers industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Hansoh Pharmaceutical Group Co and its competitors. Hansoh Pharmaceutical Group Co's current Shares Outstanding (EOP) is 6,054 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hansoh Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Hansoh Pharmaceutical Group Co (HNSPF) is currently considered Modestly Overvalued. The stock's GF Value™ is $3.00, compared to a current price of $3.83 — trading 27.5% above its estimated fair value. The current Shares Outstanding (EOP) is 6,054 Mil. Hansoh Pharmaceutical Group Co's overall GF Score™ is 90/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Hansoh Pharmaceutical Group Co (HNSPF), the current Shares Outstanding (EOP) is 6,054 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hansoh Pharmaceutical Group Co (HNSPF) Overvalued in 2026?

Based on GuruFocus' analysis, Hansoh Pharmaceutical Group Co stock appears to be overvalued. The current stock price of $3.83 is trading 27.5% above its estimated GF Value™ of $3.00. GuruFocus considers Hansoh Pharmaceutical Group Co to be Modestly Overvalued.

Key valuation signals for HNSPF:

  • Shares Outstanding (EOP): 6,054 Mil
  • GF Value™: $3.00 vs. price of $3.83 (27.5% above fair value)
  • GF Score™: 90/100

No single metric tells the full story. See the HNSPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Hansoh Pharmaceutical Group Co Business Description

Address No. 287 Xiangke Road, Pudong New Area, Shanghai, CHN
Hansoh Pharmaceutical Group Co Ltd is an investment holding company. The company were principally engaged in the research and development, production and sale of a series of pharmaceutical products in the People's Republic of China. It focuses on disease therapeutic areas such as oncology, anti-infectives, CNS, metabolism and immunology. The majority of Group's revenue was generated from the sale of pharmaceutical products in Chinese mainland.
90GF Score

Get the complete analysis for HNSPF

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.83
Price
$3.00
GF Value